Radiotherapy for lung cancer: Clinical impact of recent technical advances

Lung Cancer

Volumn 64, Issue 1, 2009, Pages 1-8

  Haasbeek, Cornelis J A ^a   Slotman, Ben J ^a   Senan, Suresh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gated radiotherapy; Image guided; Lung cancer; Radiotherapy; Stereotactic radiotherapy

Indexed keywords

ACCURACY; ADAPTIVE RADIATION; CANCER CONTROL; CANCER RADIOTHERAPY; COMPUTER PROGRAM; CONE BEAM COMPUTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DOSIMETRY; HUMAN; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; STEREOTACTIC RADIOTHERAPY; TREATMENT PLANNING;

HUMANS; LUNG NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 61449238276     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.07.008     Document Type: Review

References (56)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Onishi H., Shirato H., Nagata Y., Hiraoka M., Fujino M., Gomi K., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2 (2007) S94-100
3. Lagerwaard F.J., Haasbeek C.J., Smit E.F., Slotman B.J., and Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70 (2008) 685-692
4. Qiao X., Tullgren O., Lax I., Sirzen F., and Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 41 (2003) 1-11
5. Non-small-cell lung cancer collaborative group. Chemotherapy for non-small cell lung cancer. Non-small cell lung cancer collaborative group chemotherapy for non-small cell lung cancer Cochrane Database of Systematic Reviews: Reviews 2000 Issue 2 John Wiley & Sons, Ltd. Chichester, UK, DOI: 10 1002/14651858 CD002139 2000.
6. Okawara G., Mackay J.A., Evans W.K., and Ung Y.C. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 1 (2006) 377-393
7. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
8. Albain K.S., Swann R.S., Rusch V.R., Turrisi A.T., Shepherd F.A., Smith C.J., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 23 (2005) 7014 [Meeting abstracts]
9. Verellen D., Ridder M.D., Linthout N., Tournel K., Soete G., and Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer 7 (2007) 949-960
10. Giraud P., Antoine M., Larrouy A., Milleron B., Callard P., De R.Y., et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 48 (2000) 1015-1024
11. Grills I.S., Fitch D.L., Goldstein N.S., Yan D., Chmielewski G.W., Welsh R.J., et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys 69 (2007) 334-341
12. Yuan Sr. S., Yu J., Sun Jr. X., and Li M. Three-dimensional conformal involved-field radiotherapy for stage III non-small cell lung cancer. J Clin Oncol 24 (2006) 7044 [Meeting abstracts]
13. Senan S., De Ruysscher D., Giraud P., Mirimanoff R., and Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71 (2004) 139-146
14. Keall P. Four-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol 14 (2004) 81-90
15. Haasbeek C.J., Lagerwaard F.J., Cuijpers J.P., Slotman B.J., and Senan S. Is adaptive treatment planning required for stereotactic radiotherapy of stage I non-small-cell lung cancer?. Int J Radiat Oncol Biol Phys 67 (2007) 1370-1374
16. van der Geld Y.G., Lagerwaard F.J., van Sornsen de Koste J.R., Cuijpers J.P., Slotman B.J., and Senan S. Reproducibility of target volumes generated using uncoached four-dimensional CT scans for peripheral lung cancer. Radiat Oncol 1 (2006) 43
17. Underberg R.W., Lagerwaard F.J., Slotman B.J., Cuijpers J.P., and Senan S. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. Int J Radiat Oncol Biol Phys 62 (2005) 554-560
18. Underberg R.W., van Sornsen de Koste J.R., Lagerwaard F.J., Vincent A., Slotman B.J., and Senan S. A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. Radiat Oncol 1 (2006) 8
19. Piet A.H., Lagerwaard F.J., Kunst P.W., van Sornsen de Koste J.R., Slotman B.J., and Senan S. Can mediastinal nodal mobility explain the low yield rates for transbronchial needle aspiration without real-time imaging?. Chest 131 (2007) 1783-1787
20. Donnelly E.D., Parikh P.J., Lu W., Zhao T., Lechleiter K., Nystrom M., et al. Assessment of intrafraction mediastinal and hilar lymph node movement and comparison to lung tumor motion using four-dimensional CT. Int J Radiat Oncol Biol Phys 69 (2007) 580-588
21. Pantarotto JR, Piet AH, Vincent A, van Sornsen de Koste JR, Senan S. Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies. Int J Radiat Oncol Biol Phys 2008;abstract in proceedings of ASTRO 2008.
22. Lee P.C., Port J.L., Korst R.J., Liss Y., Meherally D.N., and Altorki N.K. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 84 (2007) 177-181
23. Al-Sarraf N., Aziz R., Gately K., Lucey J., Wilson L., McGovern E., et al. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 33 (2008) 104-109
24. van Tinteren H., Hoekstra O.S., Smit E.F., van den Bergh J.H., Schreurs A.J., Stallaert R.A., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359 (2002) 1388-1393
25. Ung Y.C., Maziak D.E., Vanderveen J.A., Smith C.A., Gulenchyn K., Lacchetti C., et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 99 (2007) 1753-1767
26. Mac Manus M.P., and Hicks R.J. Impact of PET on radiation therapy planning in lung cancer. Radiol Clin N Am 45 (2007) 627-638
27. Nestle U., Schaefer-Schuler A., Kremp S., Groeschel A., Hellwig D., Rube C., et al. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 453-462
28. Faria S.L., Menard S., Devic S., Sirois C., Souhami L., Lisbona R., et al. Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys 70 (2008) 1035-1038
29. Van Baardwijk A., Bosmans G., van Suylen R.J., Van Kroonenburgh M., Hochstenbag M., Geskes G., et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol 87 (2008) 55-58
30. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 (2005) 112-117
31. Lin Z., Mechalakos J., Nehmeh S., Schoder H., Lee N., Humm J., et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on (18)F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 70 (2008) 1219-1228
32. Townsend D.W. Multimodality imaging of structure and function. Phys Med Biol 53 (2008) R1-R39
33. Westerterp M., Pruim J., Oyen W., Hoekstra O., Paans A., Visser E., et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 34 (2007) 392-404
34. de Jaeger K., Hoogeman M.S., Engelsman M., Seppenwoolde Y., Damen E.M., Mijnheer B.J., et al. Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: re-evaluation of dose in normal lung tissue. Radiother Oncol 69 (2003) 1-10
35. Grills I.S., Yan D., Martinez A.A., Vicini F.A., Wong J.W., and Kestin L.L. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 57 (2003) 875-890
36. Grills I.S., Hugo G., Kestin L.L., Galerani A.P., Chao K.K., Wloch J., et al. Image-guided radiotherapy via daily online cone-beam CT substantially reduces margin requirements for stereotactic lung radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 1045-1056
37. Keall P., Vedam S., George R., Bartee C., Siebers J., Lerma F., et al. The clinical implementation of respiratory-gated intensity-modulated radiotherapy. Med Dosim 31 (2006) 152-162
38. Spoelstra F.O., van Sornsen de Koste J.R., Cuijpers J.P., Lagerwaard F.J., Slotman B.J., and Senan S. Analysis of reproducibility of respiration-triggered gated radiotherapy for lung tumors. Radiother Oncol 87 (2008) 59-64
39. Fowler J.F., Tome W.A., Fenwick J.D., and Mehta M.P. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 60 (2004) 1241-1256
40. Timmerman R.D., Park C., and Kavanagh B.D. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2 (2007) S101-S112
41. Haasbeek C.J., Senan S., Smit E.F., Paul M.A., Slotman B.J., and Lagerwaard F.J. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 13 (2008) 309-319
42. Takeda T., Takeda A., Kunieda E., Ishizaka A., Takemasa K., Shimada K., et al. Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol 182 (2004) 1123-1128
43. Takeda A., Kunieda E., Takeda T., Tanaka M., Sanuki N., Fujii H., et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1057-1065
44. Damhuis R., Coonar A., Plaisier P., Dankers M., Bekkers J., Linklater K., et al. A case-mix model for monitoring of postoperative mortality after surgery for lung cancer. Lung Cancer 51 (2006) 123-129
45. Nystrom H., and Thwaites D.I. Physics and high-technology advances in radiotherapy: are they still worth it?. Radiother Oncol 86 (2008) 1-3
46. Norlund A. Costs of radiotherapy. Acta Oncol 42 (2003) 411-415
47. Warren J.L., Yabroff K.R., Meekins A., Topor M., Lamont E.B., and Brown M.L. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100 (2008) 888-897
48. Hong T.S., Ritter M.A., Tome W.A., and Harari P.M. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer 92 (2005) 1819-1824
49. Allen A.M., Czerminska M., Janne P.A., Sugarbaker D.J., Bueno R., Harris J.R., et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65 (2006) 640-645
50. Rice D.C., Smythe W.R., Liao Z., Guerrero T., Chang J.Y., McAleer M.F., et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69 (2007) 350-357
51. De Neve W., and De Wagter C. Lethal pneumonitis in a phase I study of chemotherapy and IMRT for NSCLC: the need to investigate the accuracy of dose computation. Radiother Oncol 75 (2005) 246-247
52. Holloway C.L., Robinson D., Murray B., Amanie J., Butts C., Smylie M., et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 73 (2004) 285-287
53. Bentzen S.M. Randomized controlled trials in health technology assessment: overkill or overdue?. Radiother Oncol 86 (2008) 142-147
54. Senan S., Chapet O., Lagerwaard F.J., and Ten Haken R.K. Defining target volumes for non-small cell lung carcinoma. Semin Radiat Oncol 14 (2004) 308-314
55. Keall P., Mageras G.S., Balter J.M., Emery R.S., Forster K.M., and Jiang S.B. The management of respiratory motion in radiation oncology report of AAPM task group 76. Med Phys 33 (2006) 3874-3900
56. Keall P.J., Joshi S., Vedam S.S., Siebers J.V., Kini V.R., and Mohan R. Four-dimensional radiotherapy planning for DMLC-based respiratory motion tracking. Med Phys 32 (2005) 942-951